Radiopharmaceuticals Gold Rush: Why Novartis and Lilly Are Racing to Buy Theranostics.

Oncology InvestmentsPharma M&APrecision MedicineRadiopharmaceuticalsTheranosticsmedical isotopesradioligand therapy

This report explores the aggressive investment pursuits of major pharmaceutical companies in the field of radiopharmaceuticals, focusing on Novartis and Lilly. It delves into the strategic moves by these companies to capture significant market share in precision oncology and theranostics. The report outlines the growth potential of this field, driven by advances in personalized medicine and a growing demand for targeted cancer therapies. It also examines the impact of recent mergers and acquisitions in shaping the industry landscape, along with regulatory and reimbursement challenges that influence market expansion.

Researcher

Elsayed Abdelwadod, Ghost Research

PublishedMarch 2026

Perspective.

PurposeTo analyze investment strategies in radiopharmaceuticals and their impact on the healthcare industry.

AudienceIndustry analysts, healthcare investors, pharmaceutical companies, and policy makers.

Special EmphasisInnovation and strategic M&A activities.

95Pages of Deep Analysis

129Curated Credible Sources

23Proprietary AI Visuals

22Data Analysis Tables

$495

Elsayed Abdelwadod

7+ Years of Experience

Sectors & Industries

HealthCare

Functions & Expertise

Healthcare & Life SciencesMarket Intelligence

Have questions? Our Research Desk is here to help

Top Insights.

Theranostics is evolving from single-asset trades to platform-based investments.Manufacturing capability is crucial for gaining market advantage in radiopharmaceuticals.Integration of diagnostics and therapeutics is key to future oncology strategies.Early investments are benefiting from M&A activities with high premiums.Expansion in the sector is driven by regulatory changes and demand for targeted therapies.

Key Questions Answered.

95Pages of Deep Analysis

23Proprietary AI Visuals

129Curated Credible Sources

22Data Analysis Tables

Summary.

Radiopharmaceuticals are rapidly transitioning from niche to mainstream in precision oncology, with Novartis and Lilly leading M&A activities. This sector has an expected CAGR of 7.8% until 2033, driven by isotope accessibility and manufacturing scale. Major deals like BMS’s $4.1 billion acquisition of RayzeBio highlight the strategic focus on alpha emitters.

Emerging trends include increasing regulatory focus on dose optimization and geographic expansion in Asia. Supply chain resilience remains crucial, as highlighted by DOE's $32 million investment in domestic isotope production. Investors are advised to adopt a portfolio strategy, balancing commercialized platforms with emerging alpha technologies to capture growth dynamics.

Radiopharmaceuticals Gold Rush: Why Novartis and Lilly Are Racing to Buy Theranostics.

Perspective.

Elsayed Abdelwadod

1What is the primary focus of theranostics in oncology?

2Why is manufacturing capacity important in radiopharmaceuticals?

3What are the strategic benefits of early M&A in this sector?

4Which regions show significant growth potential for radiopharmaceuticals?

5How do regulatory changes impact the radiopharmaceutical market?

Summary.